Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia

results from the JPLSG AML-05 study

Akira Shimada, Yuka Iijima-Yamashita, Akio Tawa, Daisuke Tomizawa, Miho Yamada, Shiba Norio, Tomoyuki Watanabe, Takashi Taga, Shotaro Iwamoto, Kiminori Terui, Hiroshi Moritake, Akitoshi Kinoshita, Hiroyuki Takahashi, Hideki Nakayama, Katsuyoshi Koh, Hiroaki Goto, Yoshiyuki Kosaka, Akiko Moriya Saito, Nobutaka Kiyokawa, Keizo Horibe & 5 others Yusuke Hara, Kentaro Oki, Yasuhide Hayashi, Shiro Tanaka, Souichi Adachi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AMLFLT3-ITD) is associated with poor prognosis. We evaluated the results of the AML-05 study, in which all AMLFLT3-ITD patients were assigned to receive hematopoietic stem cell transplantation (HSCT) in the first remission (1CR). We also investigated the effects of additional genetic alterations on FLT3-ITD. The 5-year overall survival (OS) and event-free survival (EFS) rates among the 47 AMLFLT3-ITD patients were 42.2 and 36.8%, respectively. The 5-year disease-free survival rate among 29 patients without induction failure was 58.4%. We defined the allelic ratio (AR) of FLT3-ITD to WT > 0.7 as high. Significant differences were found in OS (AR-high, 20% vs. AR-low, 66%, p < 0.001) and EFS (13 vs. 50%, p = 0.004). All five patients with concurrent NPM1 mutations survived, while seven of eight patients who expressed the NUP98-NSD1 chimera failed to achieve 1CR and died. Multivariate analysis revealed that AR > 0.7 and expression of the NUP98-NSD1 chimera strongly impacted OS and EFS. Although all the AMLFLT3-ITD patients received HSCT at 1CR, the treatment outcome of AMLFLT3-ITD patients did not improve compared with those in a previous study. Heterogeneity was observed among AMLFLT3-ITD patients.

Original languageEnglish
Pages (from-to)586-595
Number of pages10
JournalInternational Journal of Hematology
Volume107
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Acute Myeloid Leukemia
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Survival
Therapeutics
Survival Rate
Protein-Tyrosine Kinases

Keywords

  • Alleric ratio
  • AML
  • Childhood
  • FLT3-ITD
  • NUP98-NSD1

ASJC Scopus subject areas

  • Hematology

Cite this

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia : results from the JPLSG AML-05 study. / Shimada, Akira; Iijima-Yamashita, Yuka; Tawa, Akio; Tomizawa, Daisuke; Yamada, Miho; Norio, Shiba; Watanabe, Tomoyuki; Taga, Takashi; Iwamoto, Shotaro; Terui, Kiminori; Moritake, Hiroshi; Kinoshita, Akitoshi; Takahashi, Hiroyuki; Nakayama, Hideki; Koh, Katsuyoshi; Goto, Hiroaki; Kosaka, Yoshiyuki; Saito, Akiko Moriya; Kiyokawa, Nobutaka; Horibe, Keizo; Hara, Yusuke; Oki, Kentaro; Hayashi, Yasuhide; Tanaka, Shiro; Adachi, Souichi.

In: International Journal of Hematology, Vol. 107, No. 5, 01.05.2018, p. 586-595.

Research output: Contribution to journalArticle

Shimada, A, Iijima-Yamashita, Y, Tawa, A, Tomizawa, D, Yamada, M, Norio, S, Watanabe, T, Taga, T, Iwamoto, S, Terui, K, Moritake, H, Kinoshita, A, Takahashi, H, Nakayama, H, Koh, K, Goto, H, Kosaka, Y, Saito, AM, Kiyokawa, N, Horibe, K, Hara, Y, Oki, K, Hayashi, Y, Tanaka, S & Adachi, S 2018, 'Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study', International Journal of Hematology, vol. 107, no. 5, pp. 586-595. https://doi.org/10.1007/s12185-017-2395-x
Shimada, Akira ; Iijima-Yamashita, Yuka ; Tawa, Akio ; Tomizawa, Daisuke ; Yamada, Miho ; Norio, Shiba ; Watanabe, Tomoyuki ; Taga, Takashi ; Iwamoto, Shotaro ; Terui, Kiminori ; Moritake, Hiroshi ; Kinoshita, Akitoshi ; Takahashi, Hiroyuki ; Nakayama, Hideki ; Koh, Katsuyoshi ; Goto, Hiroaki ; Kosaka, Yoshiyuki ; Saito, Akiko Moriya ; Kiyokawa, Nobutaka ; Horibe, Keizo ; Hara, Yusuke ; Oki, Kentaro ; Hayashi, Yasuhide ; Tanaka, Shiro ; Adachi, Souichi. / Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia : results from the JPLSG AML-05 study. In: International Journal of Hematology. 2018 ; Vol. 107, No. 5. pp. 586-595.
@article{a0dbb296f2394529891bce5facc857ea,
title = "Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study",
abstract = "Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AMLFLT3-ITD) is associated with poor prognosis. We evaluated the results of the AML-05 study, in which all AMLFLT3-ITD patients were assigned to receive hematopoietic stem cell transplantation (HSCT) in the first remission (1CR). We also investigated the effects of additional genetic alterations on FLT3-ITD. The 5-year overall survival (OS) and event-free survival (EFS) rates among the 47 AMLFLT3-ITD patients were 42.2 and 36.8{\%}, respectively. The 5-year disease-free survival rate among 29 patients without induction failure was 58.4{\%}. We defined the allelic ratio (AR) of FLT3-ITD to WT > 0.7 as high. Significant differences were found in OS (AR-high, 20{\%} vs. AR-low, 66{\%}, p < 0.001) and EFS (13 vs. 50{\%}, p = 0.004). All five patients with concurrent NPM1 mutations survived, while seven of eight patients who expressed the NUP98-NSD1 chimera failed to achieve 1CR and died. Multivariate analysis revealed that AR > 0.7 and expression of the NUP98-NSD1 chimera strongly impacted OS and EFS. Although all the AMLFLT3-ITD patients received HSCT at 1CR, the treatment outcome of AMLFLT3-ITD patients did not improve compared with those in a previous study. Heterogeneity was observed among AMLFLT3-ITD patients.",
keywords = "Alleric ratio, AML, Childhood, FLT3-ITD, NUP98-NSD1",
author = "Akira Shimada and Yuka Iijima-Yamashita and Akio Tawa and Daisuke Tomizawa and Miho Yamada and Shiba Norio and Tomoyuki Watanabe and Takashi Taga and Shotaro Iwamoto and Kiminori Terui and Hiroshi Moritake and Akitoshi Kinoshita and Hiroyuki Takahashi and Hideki Nakayama and Katsuyoshi Koh and Hiroaki Goto and Yoshiyuki Kosaka and Saito, {Akiko Moriya} and Nobutaka Kiyokawa and Keizo Horibe and Yusuke Hara and Kentaro Oki and Yasuhide Hayashi and Shiro Tanaka and Souichi Adachi",
year = "2018",
month = "5",
day = "1",
doi = "10.1007/s12185-017-2395-x",
language = "English",
volume = "107",
pages = "586--595",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia

T2 - results from the JPLSG AML-05 study

AU - Shimada, Akira

AU - Iijima-Yamashita, Yuka

AU - Tawa, Akio

AU - Tomizawa, Daisuke

AU - Yamada, Miho

AU - Norio, Shiba

AU - Watanabe, Tomoyuki

AU - Taga, Takashi

AU - Iwamoto, Shotaro

AU - Terui, Kiminori

AU - Moritake, Hiroshi

AU - Kinoshita, Akitoshi

AU - Takahashi, Hiroyuki

AU - Nakayama, Hideki

AU - Koh, Katsuyoshi

AU - Goto, Hiroaki

AU - Kosaka, Yoshiyuki

AU - Saito, Akiko Moriya

AU - Kiyokawa, Nobutaka

AU - Horibe, Keizo

AU - Hara, Yusuke

AU - Oki, Kentaro

AU - Hayashi, Yasuhide

AU - Tanaka, Shiro

AU - Adachi, Souichi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AMLFLT3-ITD) is associated with poor prognosis. We evaluated the results of the AML-05 study, in which all AMLFLT3-ITD patients were assigned to receive hematopoietic stem cell transplantation (HSCT) in the first remission (1CR). We also investigated the effects of additional genetic alterations on FLT3-ITD. The 5-year overall survival (OS) and event-free survival (EFS) rates among the 47 AMLFLT3-ITD patients were 42.2 and 36.8%, respectively. The 5-year disease-free survival rate among 29 patients without induction failure was 58.4%. We defined the allelic ratio (AR) of FLT3-ITD to WT > 0.7 as high. Significant differences were found in OS (AR-high, 20% vs. AR-low, 66%, p < 0.001) and EFS (13 vs. 50%, p = 0.004). All five patients with concurrent NPM1 mutations survived, while seven of eight patients who expressed the NUP98-NSD1 chimera failed to achieve 1CR and died. Multivariate analysis revealed that AR > 0.7 and expression of the NUP98-NSD1 chimera strongly impacted OS and EFS. Although all the AMLFLT3-ITD patients received HSCT at 1CR, the treatment outcome of AMLFLT3-ITD patients did not improve compared with those in a previous study. Heterogeneity was observed among AMLFLT3-ITD patients.

AB - Acute myeloid leukemia harboring internal tandem duplication of FMS-like tyrosine kinase 3 (AMLFLT3-ITD) is associated with poor prognosis. We evaluated the results of the AML-05 study, in which all AMLFLT3-ITD patients were assigned to receive hematopoietic stem cell transplantation (HSCT) in the first remission (1CR). We also investigated the effects of additional genetic alterations on FLT3-ITD. The 5-year overall survival (OS) and event-free survival (EFS) rates among the 47 AMLFLT3-ITD patients were 42.2 and 36.8%, respectively. The 5-year disease-free survival rate among 29 patients without induction failure was 58.4%. We defined the allelic ratio (AR) of FLT3-ITD to WT > 0.7 as high. Significant differences were found in OS (AR-high, 20% vs. AR-low, 66%, p < 0.001) and EFS (13 vs. 50%, p = 0.004). All five patients with concurrent NPM1 mutations survived, while seven of eight patients who expressed the NUP98-NSD1 chimera failed to achieve 1CR and died. Multivariate analysis revealed that AR > 0.7 and expression of the NUP98-NSD1 chimera strongly impacted OS and EFS. Although all the AMLFLT3-ITD patients received HSCT at 1CR, the treatment outcome of AMLFLT3-ITD patients did not improve compared with those in a previous study. Heterogeneity was observed among AMLFLT3-ITD patients.

KW - Alleric ratio

KW - AML

KW - Childhood

KW - FLT3-ITD

KW - NUP98-NSD1

UR - http://www.scopus.com/inward/record.url?scp=85042796956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042796956&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2395-x

DO - 10.1007/s12185-017-2395-x

M3 - Article

VL - 107

SP - 586

EP - 595

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -